Low enrollment in a phase III trial and a missed primary endpoint sent Aridis Pharmaceuticals Inc.’s shares tumbling by 35% on Jan. 26, although the company’s AR-301 (tosatoxumab) showed superior efficacy over the control group in Staphylococcus aureus ventilator-associated pneumonia (VAP) patients.
Bio-Rad Laboratories Inc. signed a $170 million deal to acquire all the outstanding shares of molecular diagnostics subsidiary Curiosity Diagnostics SpZoo from Scope Fluidics SA. The deal consists of approximately $100 million in cash and up to $70 million in future milestone payments. The pre-commercial platform company is the developer of a CE-marked 15-minute point-of-care (POC) rapid PCR system which tests for SARS-CoV-2 virus and methicillin-resistant or-sensitive Staphylococcus aureus bacteria (MRSA/MSSA).
The data safety monitoring board overseeing Contrafect Corp.’s phase III study of exebacase, a hydrolase stimulator for treating Staphylococcus aureus bacteremia, recommended the study be stopped. In an interim analysis, the board said the conditional power of the study was below the prespecified threshold for futility.
COVID-19 is the unwanted gift that keeps on giving. The U.S. CDC unwrapped one of those “presents” in a July 12 report that showed the threat of antimicrobial-resistant (AMR) infections has worsened — with resistant hospital-onset infections and deaths in the U.S. each increasing at least 15% during the first year of the pandemic.
The accepted wisdom that resistance to antibiotics is a modern phenomenon driven by their overuse is called into question by new research showing the genes that give methicillin-resistant Staphylococcusaureus (MRSA) its superbug status existed in nature long before antibiotics were first deployed in the clinic.
“I was not always someone who would have advertised probiotics,” Michael Otto told BioWorld. And it’s easy to see why. At this point, probiotics are more often dubious wellness offerings than evidence-based therapeutics. Part of the issue is that the mechanisms by which probiotics are supposed to exert their effects are mostly vague. Molecular mechanisms that could account for claimed health benefits are few and far between. But Otto, who is chief of the pathogen molecular genetics section at the National Institutes of Allergy and Infectious Disease, and his colleagues have identified one such molecular mechanism.
Micurx Pharmaceuticals Inc. has won marketing approval from China's NMPA for its lead antibacterial, contezolid, for treating adults with complicated skin and soft tissue infection (cSSTI), marking the first NDA for the Shanghai drugmaker. Set to be marketed as Youxitai in China, Micurx discovered the new-generation oral oxazolidinone antibiotic, developing it over 12 years. It’s designed to treat multidrug-resistant gram-positive bacteria such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci.
PERTH, Australia – Synthetic cannabinoid company Botanix Pharmaceuticals Ltd. announced top-line data from a phase IIa study showing that two different formulations of BTX-1801, a synthetic cannabidiol (CBD), eradicated Staphylococcus aureus (staph) in the nose, meeting study endpoints for safety and efficacy.
PERTH, Australia – Synthetic cannabinoid company Botanix Pharmaceuticals Ltd. announced top-line data from a phase IIa study showing that two different formulations of BTX-1801, a synthetic cannabidiol, eradicated Staphylococcus aureus (staph) in the nose, meeting study endpoints for safety and efficacy.